Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer

被引：0
|
作者：
Dan Lu
Chunze Li
Matthew Riggs
Daniel Polhamus
Jonathan French
Priya Agarwal
Shang-Chiung Chen
Shweta Vadhavkar
Monika Patre
Alexander Strasak
Angelica Quartino
Jin Yan Jin
Sandhya Girish
机构：
[1] Genentech,Department of Clinical Pharmacology
[2] Inc.,undefined
[3] Metrum Research Group,undefined
[4] F. Hoffmann-La Roche Ltd.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Trastuzumab emtansine (T-DM1); HER2; Pharmacokinetics; Previously untreated metastatic breast cancer; MARIANNE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：175 / 185
页数：10
相关论文
共 50 条
  • [1] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
    Lu, Dan
    Li, Chunze
    Riggs, Matthew
    Polhamus, Daniel
    French, Jonathan
    Agarwal, Priya
    Chen, Shang-Chiung
    Vadhavkar, Shweta
    Patre, Monika
    Strasak, Alexander
    Quartino, Angelica
    Jin, Jin Yan
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 175 - 185
  • [2] Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Lu, Dan
    Burris, Howard A., III
    Wang, Bei
    Dees, E. Claire
    Cortes, Javier
    Joshi, Amita
    Gupta, Manish
    Yi, Joo-Hee
    Chu, Yu-Waye
    Shih, Ted
    Fang, Liang
    Girish, Sandhya
    CURRENT DRUG METABOLISM, 2012, 13 (07) : 911 - 922
  • [3] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [4] Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
    Chunze Li
    Bei Wang
    Dan Lu
    Jin Y. Jin
    Yuying Gao
    Kiyoshi Matsunaga
    Yuriko Igawa
    Ihsan Nijem
    Michael Lu
    Alexander Strasak
    Nataliya Chernyukhin
    Sandhya Girish
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 547 - 558
  • [5] Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
    Krop, Ian E.
    Modi, Shanu
    LoRusso, Patricia M.
    Pegram, Mark
    Guardino, Ellie
    Althaus, Betsy
    Lu, Dan
    Strasak, Alexander
    Elias, Anthony
    BREAST CANCER RESEARCH, 2016, 18
  • [6] Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
    Li, Chunze
    Wang, Bei
    Lu, Dan
    Jin, Y.
    Gao, Yuying
    Matsunaga, Kiyoshi
    Igawa, Yuriko
    Nijem, Ihsan
    Lu, Michael
    Strasak, Alexander
    Chernyukhin, Nataliya
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 547 - 558
  • [7] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
  • [8] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    Jacot, William
    Pons, Elvire
    Frenel, Jean-Sebastien
    Guiu, Severine
    Levy, Christelle
    Heudel, Pierre Etienne
    Bachelot, Thomas
    D'Hondt, Veronique
    Darlix, Amelie
    Firmin, Nelly
    Romieu, Gilles
    Thezenas, Simon
    Dalenc, Florence
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318
  • [9] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    William Jacot
    Elvire Pons
    Jean-Sébastien Frenel
    Séverine Guiu
    Christelle Levy
    Pierre Etienne Heudel
    Thomas Bachelot
    Véronique D’Hondt
    Amélie Darlix
    Nelly Firmin
    Gilles Romieu
    Simon Thezenas
    Florence Dalenc
    Breast Cancer Research and Treatment, 2016, 157 : 307 - 318
  • [10] Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Harada, Naoki
    Fujimoto-Ouchi, Kaori
    ONCOLOGY REPORTS, 2013, 30 (03) : 1087 - 1093
12345